Amgen (AMGN) - Stock Price & Dividends

Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US0311621009

Cancer, Arthritis, Osteoporosis, Anemia, Heart

Amgen Inc. is a leading biotechnology company that discovers, develops, manufactures, and delivers life-changing human therapeutics worldwide. The company's portfolio includes a range of innovative medicines that treat various diseases and conditions, such as Enbrel for plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; and Prolia for postmenopausal women with osteoporosis.

Amgen's product lineup also includes XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS for relapsed or refractory multiple myeloma; Aranesp for anemia; and EVENITY for osteoporosis in postmenopausal men and women. Additionally, the company offers Vectibix for wild-type RAS metastatic colorectal cancer; BLINCYTO for acute lymphoblastic leukemia; TEPEZZA for thyroid eye disease; and KRYSTEXXA for chronic refractory gout.

Amgen's commitment to innovation is evident in its extensive research and development pipeline, which focuses on advancing new treatments for various diseases, including cancer, cardiovascular disease, and inflammatory disorders. The company collaborates with other industry leaders, such as AstraZeneca, Novartis, UCB, Kyowa Kirin, and BeiGene, to accelerate the development and commercialization of new medicines.

As a global healthcare leader, Amgen serves a diverse range of healthcare providers, including physicians, clinics, dialysis centers, hospitals, and pharmacies. The company's products are distributed through a network of pharmaceutical wholesale distributors and direct-to-consumer channels, ensuring that its life-changing medicines reach patients in need worldwide. Founded in 1980, Amgen Inc. is headquartered in Thousand Oaks, California, and continues to drive innovation and improvement in human health.

For more information, please visit Amgen's official website at https://www.amgen.com.

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for Amgen (AMGN) - Stock Price & Dividends

Overall Trend and Yearly Seasonality

Drawdown / Underwater Chart for Amgen (AMGN) - Stock Price & Dividends

AMGN Stock Overview

Market Cap in USD 166,236m
Sector Healthcare
Industry Drug Manufacturers - General
GiC SubIndustry Biotechnology
TER 0.00%
IPO / Inception 1983-06-17

AMGN Stock Ratings

Growth 5y 68.6
Fundamental 20.1
Dividend 8.29
Rel. Performance vs Sector 2.77
Analysts 3.67/5
Fair Price Momentum 319.68 USD
Fair Price DCF 375.34 USD

AMGN Dividends

Yield 12m 2.84%
Yield on Cost 5y 5.51%
Dividends CAGR 5y 7.99%
Payout Consistency 100.0%

AMGN Growth Ratios

Growth 12m 39.93%
Growth Correlation 12m 63%
Growth Correlation 3m 42%
CAGR 5y 14.14%
CAGR/Mean DD 5y 1.73
Sharpe Ratio 12m 1.41
Alpha vs SP500 12m 24.33
Beta vs SP500 5y weekly 0.47
ValueRay RSI 61.61
Volatility GJR Garch 1y 22.01%
Price / SMA 50 4.79%
Price / SMA 200 10.06%
Current Volume 6933.3k
Average Volume 20d 2472.9k

External Links for AMGN Stock

News
Wall Street JournalBenzingaYahoo Finance
Tweets
XStocktwits
Fund Manager Positions
DataromaStockcircle
What is the price of AMGN stocks?
As of June 22, 2024, the stock is trading at USD 308.16 with a total of 6,933,257 shares traded.
Over the past week, the price has changed by +3.19%, over one month by -2.12%, over three months by +12.06% and over the past year by +39.97%.
What are the forecast for AMGN stock price target?
According to ValueRays Forecast Model, AMGN Amgen will be worth about 347.1 in June 2025. The stock is currently trading at 308.16. This means that the stock has a potential upside of +12.63%.
Issuer Forecast Upside
Wallstreet Target Price 318.7 3.43
Analysts Target Price 258.8 -16.0
ValueRay Target Price 347.1 12.6

Amgen Inc: A Pioneering Biotech Giant

Founded in 1980, Amgen Inc has grown from a modest biotechnology workshop to one of the world's leading independent biopharmaceutical companies. Rooted in the scientific innovation of recombinant DNA technology, Amgen's mission has been to serve patients by transforming the promise of science and biotechnology into therapies that have the power to restore health or even save lives.

The Core of Amgen

Amgen's core business revolves around the development, manufacturing, and commercialization of innovative human therapeutics. The company has a diverse portfolio of medicines that target various diseases, including cancer, kidney disease, rheumatoid arthritis, and bone disease. Among its most notable products are Neulasta® (pegfilgrastim), used to prevent infections in patients undergoing cancer chemotherapy; Enbrel® (etanercept), for the treatment of several autoimmune diseases; and Otezla® (apremilast), which treats psoriasis and psoriatic arthritis.

Amgen’s Side Businesses and Expansion

Beyond its primary focus on biopharmaceuticals, Amgen has expanded into related fields to bolster its market presence and serve more patient needs. The company actively engages in partnerships and acquisitions that align with its core mission. For instance, Amgen has made significant advances in precision medicine and digital health. This includes investments in companies developing wearable technology for health monitoring and platforms for advanced data analysis to improve therapeutic outcomes.

Amgen’s Current Market Status

As of 2023, Amgen continues to be a dominant player in the biopharmaceutical industry. Despite facing challenges such as patent expirations and competition from biosimilars, the company's strong emphasis on research and development has enabled it to maintain a robust pipeline of potential new treatments. Financially, Amgen remains solid, with a consistent track record of revenue growth and shareholder returns. The company’s strategic focus on expanding its global footprint and investing in innovation underscores its commitment to sustaining growth and remaining competitive in a rapidly evolving industry.